Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial

•The full benefits of pneumococcal conjugate vaccines in children are demonstrated.•Various outcomes contribute to the benefits of pneumococcal conjugate vaccines.•Over 95% of the benefits in PCV-vaccinated children were seen for otitis.•Net absolute reduction is essential from the public health perspective. Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the pneumococcal disease burden by using the vaccine-preventable disease incidence (VPDI) of PHiD-CV10 vaccine (GSK) in our clinical trial setting. Finnish Invasive Pneumococcal disease (FinIP) trial was a cluster-randomized, double-blind trial in children